HER2 status in elderly women with breast cancer

Journal of Geriatric Oncology

Volumn 4, Issue 4, 2013, Pages 362-367

  Laird Fick, Heather S ^a   Gardiner, Joseph C ^b   Tokala, Hemasri ^a,c   Patel, Priyank ^a,c   Wei, Sainan ^a   Dimitrov, Nikolay V ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c Claire Dart Stroke Center Sparrow Hospital   (United States)

Author keywords

Biomarkers; Breast cancer; Epidemiology

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

AGE DISTRIBUTION; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; CANCER INCIDENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREND STUDY; TRIPLE NEGATIVE BREAST CANCER;

BIOMARKERS; BREAST CANCER; EPIDEMIOLOGY;

AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84884979306     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2013.05.007     Document Type: Article

References (34)

1. Honma N., Sakamoto G., Akiyama F., Esaki Y., Sawabe M., Arai T., et al. Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status. Histopathology 2003, 42(2):120-127.
2. deRijke J., Schouten L., Hillen H., Kiemeney L., Coebergh J., van den Brandt P. Breast cancer in the very elderly Dutch population. Cancer 2000, 89:1121-1133.
3. Bastiaannet E., Portielje J., van de Velde C., de Craen A., van der Velde S., Kuppen P., et al. Lack of survival gain for elderly women with breast cancer. Oncologist 2011, 16:415-423.
4. Hutchins L., Unger J., Crowley J., Coltman C., Albain K. Underrepresentation of patients 65years of age or older in cancer-treatment trials. N Engl J Med 1999, 341(27):2061-2067.
5. Javid S., Unger J., Gralow J., Moinpour C., Wozniak A., Goodwine J., et al. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). Oncologist 2012, 17:1180-1190.
6. Murthy V., Krumholz H., Gross C. Participation in cancer clinical trials: race-, sex-, and age-based disparities. J Am Med Assoc 2004, 291:2720-2726.
7. Owusu C. Clinical management update: evaluation and management of older patients with breast cancer. J Am Geriatr Soc 2009, 57:S250-S252.
8. Stewart J., Bertoni A., Staten J., Levine E., Gross C. Ann Surg Oncol 2007, 14(12):3328-3334.
9. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
10. Sauter G., Lee J., Bartlett J., Slamon D., Press M. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009, 27:1323-1333.
11. Harris C., Ward R., Dobbins T., Drew A., Pearson S. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol 2011, 22(6):1308-1317.
12. Yin W., Jiang Y., Shen Z., Shao Z., Lu J. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One 2011, 6(6):e21030.
13. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365:1273-1283.
14. Perez E., Suman V., Davidson N., Gralow J., Kaufman P., et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011, 29(34):4491-4497.
15. Blackwell K., Burstein H., Storniolo A., Rugo H., Sledge G., Aktan G., et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 2012, 30(21):2585-2592.
16. Ismael G., Hegg R., Muehlbauer S., Heinzmann D., Lum B., Kim S., et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012, 13(9):869-878.
17. Wolff A., Wang M., Li H., Pins M., Pretorius F., Rowland K., et al. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198. Breast Cancer Res Treat 2010, 121(1):111-120.
18. Dendukuri N., Khetani K., McIsaac M., Brophy J. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 2007, 176(10):1429-1434.
19. Wolff A.C., Hammond M., Schwartz J., Hagerty K., Allred D., Cote R., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131:18-43.
20. Bartlett J., Ibrahim M., Jasani B., Morgan J., Ellis I., Kay E., et al. External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. J Clin Pathol 2007 July, 60(7):816-819.
21. Paik S., Bryant J., Tan-Chiu E., Romond E., Hiller W., Park K., et al. Real-world performance of HER2 testing - national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst 2002, 94(11):852-854.
22. Press M., Sauter G., Bernstein L., Villalobos I., Mirlacher M., Zhou J., et al. Diagnostic evaluation of HER-2 as a Molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005, 11:6598-6607.
23. Perez E., Suman V., Davidson N., Martino S., Kaufman P., Lingle W., et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 2006, 24:3032-3038.
24. Press M., Slamon D., Flom K., Park J., Zhou J., Bernstein L. Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens. J Clin Oncol 2002, 20(14):3095-3105.
25. Diab S., Elledge R., Clark G. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2009, 92(7):550-556.
26. Daidone M., Coradini D., Martelli G., Veneroni S. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol 2003, 45(3):313-325.
27. Gennari R., Curigliano G., Rotmensz N., Robertson C., Colleoni M., Zurrida S., et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. Cancer 2004, 101(6):1302-1310.
28. Molino A., Giovannini M., Auriemma A., Fiorio E., Mercanti A., Mandara M., et al. Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer. Crit Rev Oncol Hematol 2006, 59(3):226-233.
29. van de Ven S.S.V., Dekker T.J., Nortier J.W., Kroep J.R. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev Oct. 2011, 37(6):422-430.
30. Collett K., Hartveit F., Skjaerven R., Maehle B. Prognostic role of oestrogen and progesterone receptors in patients with breast cancer: relation to age and lymph node status. J Clin Pathol 1996, 49(11):920-925.
31. Pujol P., Daures J., Thezenas S., Guilleux F., Rouanet P., Grenier J. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 1998, 83(4):698-705.
32. Newschaffer C., Penberthy L., Desch C., Retchin S., Whittemore M. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med 1996, 156:85-90.
33. Apple S., Lowe A., Rao P., Shintaku I., Moatamed N. Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer. Mod Pathol 2009, 22:1151-1159.
34. Arnedos M., Nerurkar A., Osin P., A'Hern R., Smith I., Dowsett M. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 2009, 20:1948-1952.